JAX receives $1M from the Mark Foundation for Cancer Research

Funds will support research into immunotherapy response rates and side effects

Immunotherapy can be a crucial tool for patients undergoing cancer treatment, vastly improving outcomes for many whose conditions would otherwise be fatal. Unfortunately a subset of these patients develop toxic autoimmune side effects to immune checkpoint inhibitor (ICI) treatment. If we could predict those individuals at risk of developing particular adverse events, interventions for such complications could be initiated in the timeliest fashion.

A new $1 million grant from the Mark Foundation for Cancer Research presented to The Jackson Laboratory will fund research to study why these side effects sometimes occur and use the power of genetics to predict better outcomes for patients. Read more

Related Posts

Business Leaders: Deborah Bronk steers Bigelow Lab expansion to boost reach, programming

Deborah Bronk is president, CEO and a senior research scientist at Bigelow Laboratory for Ocean Sciences in East Boothbay, which will...

24 March 2025

UNE retains R2 Research status, reinforcing leadership in scientific advancement

The University of New England has retained its status as one of the country’s leading research universities with the recent release...

23 March 2025

Maine college students investigate health effects of forever chemicals

Two dozen Maine college students are investigating the public health effects of forever chemicals by using zebrafish as human stand-ins and...

21 March 2025